Augtyro (repotrectinib) - BMS
Augtyro: Expiry of patents related to composition-of-matter in US in 2035 (Bristol-Myers Squibb) - Mar 2, 2025 - Annual Report 2024: Regulatory data protection in US until 2035 
Commercial • Patent Lung Cancer • Non Small Cell Lung Cancer • Oncology
https://d18rn0p25nwr6d.cloudfront.net/CIK-0000014272/4e908a34-8908-477e-8d50-355caee1e05a.pdf
 
Mar 2, 2025
 
 
3e9ae0fc-0778-4fa9-8d8f-be312fc32d6c.png